利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

124 条记录 (耗时 0.026 秒)

    Polymorph salt of a pryridazinone derivative for the treatment of arrythmia
    1.
    发明申请
    Polymorph salt of a pryridazinone derivative for the treatment of arrythmia 审中-公开
    吡咯烷酮衍生物的多晶型盐用于治疗arrythmia

    公开(公告)号：US20040266772A1

    公开(公告)日：2004-12-30

    申请号：US10484621

    申请日：2004-04-23

    发明人： Jozsef Barkoczy ,  Peter Kotay Nagy ,  Gyula Simig ,  Zsuzsa Szent-Kirallyi

    IPC分类号： A61K031/50 ,  C07D237/02

    CPC分类号： C07D237/22

    摘要： The invention relates to the new crystalline form I 5-chloro-4-null3-nullN-null2-(3,4-dimethoxy-phenyl)-ethylnull-N-methylaminonull-propylaminonull-3-null2Hnull-pyridazinone fumarate, a process for the preparation thereof, pharmaceutical compositions containing the same and the use of said new polymorph for the treatment of arrhythmia. 1

    摘要翻译： 本发明涉及新的结晶形式I 5-氯-4- [3- [N- [2-（3,4-二甲氧基 - 苯基） - 乙基] -N-甲基氨基] - 丙基氨基] -3- [2H] - 哒嗪酮富马酸盐，其制备方法，含有它们的药物组合物和所述新型多晶型物用于治疗心律失常的用途。

    Methods for remodeling neuronal and cardiovascular pathways
    2.
    发明申请
    Methods for remodeling neuronal and cardiovascular pathways 审中-公开

    公开(公告)号：US20040234619A1

    公开(公告)日：2004-11-25

    申请号：US10869755

    申请日：2004-06-15

    申请人： Cellegy Pharmaceuticals, Inc.

    发明人： Michael A. Adams ,  Jeremy P.W. Heaton

    IPC分类号： A61K038/05 ,  A61K031/50 ,  A61K033/00 ,  A61K031/21

    CPC分类号： A61K31/519 ,  A61K31/00 ,  A61K31/502 ,  A61K31/513 ,  A61K31/5575 ,  A61K45/06

    摘要： The present invention provides a method of administration of an agent which acts to remodel neuronal or vascular pathways for the long term management of sexual dysfunction in both males and females. In a preferred embodiment, the invention provides a method of ameliorating or reversing pathogenic vascular degradative modeling in the ilio-hypogastric-pudendal arterial bed and genitalia comprising administering to a human patient in need of such treatment a therapeutically effective amount of an anti-pressor agent. The anti-pressor agent comprises one or more compounds selected from the therapeutic classes of direct vasodilators such as hydralazine and NO donors, ACE inhibitors, angiotensin-II receptor antagonists, null1-adrenergic receptor antagonists, null-adrenergic receptor antagonists, calcium channel blockers, and phosphodiesterase inhibitors. The anti-pressor agent may be co-administered with a diuretic compound, and is administered either chronically at low dose, or for short periods of time at doses higher than are typically used for the treatment of hypertension. In certain embodiments of the method of the invention, the anti-pressor agent is co-administered with a diuretic agent and/or prostaglandin-E1.

    Malonamid and malonamic ester derivatives with antithrombotic activity, their preparation, and their use
    6.
    发明申请
    Malonamid and malonamic ester derivatives with antithrombotic activity, their preparation, and their use 有权
    丙二酰胺和丙二酸酯衍生物具有抗血栓活性，其制备及其用途

    公开(公告)号：US20040034027A1

    公开(公告)日：2004-02-19

    申请号：US10634827

    申请日：2003-08-06

    申请人： Aventis Pharma Deutschland GmbH

    发明人： Manfred Schudok ,  Otmar Klingler ,  Hans-Peter Nestler ,  Hans Matter ,  Herman Schreuder

    IPC分类号： A61K031/44 ,  A61K031/50

    CPC分类号： A61K31/27 ,  A61K31/167 ,  A61K31/225 ,  C07C257/18 ,  C07C257/20

    摘要： Compounds of formula I, 1 in which R1, R2, A, and B having the definitions set forth in the claims, are valuable pharmacologically active compounds, which exhibit a strong antithrombotic effect and are suitable, for example, for treating thromboembolic diseases and restenoses. They are reversible inhibitors of the blood clotting enzyme factor VIIa and can in general be applied in conditions in which an undesired activity of factor VIIa is present or for the cure or prevention of which an inhibition of factor VIIa is intended. Also disclosed are processes for the preparation of compounds of formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

    摘要翻译： 具有权利要求中所述定义的R 1，R 2，A和B的式I化合物是有价值的药理活性化合物，其表现出很强的抗血栓形成作用，并且适用于例如 治疗血栓栓塞性疾病和再狭窄。 它们是血液凝固酶因子VIIa的可逆抑制剂，并且通常可以在其中存在不需要的因子VIIa的活性或用于治疗或预防因子VIIa的抑制的条件下使用。 还公开了制备式I化合物的方法，其用途，特别是作为药物中的活性成分，以及包含它们的药物制剂。

    Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
    7.
    发明申请
    Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity 审中-公开
    包括降低vegf活性的试剂和减少egf活性的试剂的组合

    公开(公告)号：US20040034026A1

    公开(公告)日：2004-02-19

    申请号：US10432303

    申请日：2003-05-21

    发明人： Jeannette M Wood ,  Ralf Brandt ,  Guido Bold ,  Peter Traxler

    IPC分类号： A61K031/501 ,  A61K031/50

    CPC分类号： A61K45/06 ,  A61K31/505 ,  A61K31/70 ,  A61K31/50 ,  A61K31/335 ,  A61K2300/00

    摘要： The invention relates to a combination which comprises a first active ingredient which is a vasculostatic compound and a second active ingredient which decreases the activity of the epidermal growth factor (EGF), in particular, for the delay of progression or treatment of a disease associated with deregulated angiogenesis, especially a proliferative disease; a pharmaceutical composition comprising such a combination; a commercial package comprising such a combination as a combined preparation; and to a method of treatment of a warm-blooded animal, especially a human.

    摘要翻译： 本发明涉及一种组合，其包含第一种活性成分，其为血管平滑化合物和降低表皮生长因子（EGF）活性的第二活性成分，特别是延迟进展或治疗与 放松血管生成，特别是增殖性疾病; 包含这种组合的药物组合物; 包括作为组合制剂的这种组合的商业包装; 以及治疗温血动物，特别是人的方法。

    Inhibitors of p38
    9.
    发明申请
    Inhibitors of p38 失效
    p38的抑制剂

    公开(公告)号：US20030096817A1

    公开(公告)日：2003-05-22

    申请号：US10144153

    申请日：2002-05-10

    发明人： Jeremy Green ,  Scott L. Harbeson ,  John E. Cochran

    IPC分类号： A61K031/53 ,  A61K031/513 ,  A61K031/50 ,  A61K031/505 ,  C07D237/02 ,  C07D253/04

    CPC分类号： C07D213/74 ,  C07D405/06 ,  C07D405/12 ,  C07D409/06 ,  C07D409/14 ,  C07D417/12

    摘要： The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.

    摘要翻译： 本发明涉及p38的抑制剂，其涉及细胞增殖，细胞死亡和对细胞外刺激的反应的哺乳动物蛋白激酶。 本发明还涉及生产这些抑制剂的方法。 本发明还提供包含本发明抑制剂的药物组合物和利用这些组合物治疗和预防各种疾病的方法。